Citicoline dosage

Protocol

1. 1

   Measure the dose

   Typical Citicoline dose is 500 mg (Supplement use 250 to 500 mg/day; prescription stroke-recovery dose 1,000 to 2,000 mg/day). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer 1 to 2 times daily. Half-life of 56 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   No formal cycling required; long-term continuous use documented in European prescription practice

   Open tool →
4. 4

   Monitor for side effects

   Watch for: mild GI upset; headache; restlessness; occasional insomnia with evening dosing. Stop or reduce dose if tolerability breaks down.

Why this dose

Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production.

The typical dose (500 mg) reflects Supplement use 250 to 500 mg/day; prescription stroke-recovery dose 1,000 to 2,000 mg/day. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Citicoline is administered via the oral or intravenous routes. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 1 hour after administration. Peak effect lands near 2 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Uridine metabolite plasma half-life around 56 hours; supports once or twice daily dosing

Cycling and tolerance

No formal cycling required; long-term continuous use documented in European prescription practice

Effects to expect at typical dose

• Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
• Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
• Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
• ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
• Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
• Long uridine half-life (~56 hours) supports once or twice daily dosing

Side effects and interactions

Common side effects

• mild GI upset
• headache
• restlessness
• occasional insomnia with evening dosing

Notable interactions

• anticholinergic medications (minor): partial mutual antagonism
• cholinesterase inhibitors (minor): additive cholinergic effect
• antimetabolite chemotherapy (5-FU) (minor): theoretical cytidine pathway interaction

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Citicoline profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

OTC supplement (US); Rx in most of the world

Pregnancy

Insufficient data for routine use

Legal status

Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world

Do not use if

• concurrent strong anticholinergic therapy
• established cardiovascular disease (TMAO concern, smaller than alpha-GPC)

Related research